CA Patent

CA2493000A1 — 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases

Assigned to University of Cincinnati · Expires 2004-01-29 · 22y expired

What this patent protects

The invention relates to the use of 4-(4-methylpiperazin-l-ylmethyl)-N-(4- methyl-3-(4-pyridin3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof for the treatment of mutated-RET kinase associated disease, especially mutated-RET kinase associa…

USPTO Abstract

The invention relates to the use of 4-(4-methylpiperazin-l-ylmethyl)-N-(4- methyl-3-(4-pyridin3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof for the treatment of mutated-RET kinase associated disease, especially mutated-RET kinase associated thyroid cancer.

Drugs covered by this patent

Patent Metadata

Patent number
CA2493000A1
Jurisdiction
CA
Classification
—
Expires
2004-01-29
Drug substance claim
No
Drug product claim
No
Assignee
University of Cincinnati
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.